July 14, 2025

Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Authors

EEEric D. EisenmannThe Ohio State University RSRonan SwordsOregon Health & Science University YHYing HuangFujian Medical University

Discussion

Member takes

Implication

Phase 1b/2 trial examines the effects of decitabine and TP-0903 on treatment response and survival in AML patients, indicating potential benefits for elderly populations.

Key Points

MAIN FINDING: The trial evaluates TP-0903 and decitabine's effects on treatment response in acute myeloid leukemia patients aged 60 or older.
KEY EVIDENCE: Results demonstrate improvements in treatment response duration and overall survival among patients receiving TP-0903 and decitabine.
APPROACH: The study follows a phase 1b/2 design, focusing on patients with untreated acute myeloid leukemia, mutant TP53, and complex karyotype.
SIGNIFICANCE: These findings highlight a potential new treatment avenue for older patients with aggressive leukemia, aiming to improve outcomes.

Cite This Study

Eisenmann et al. (2025) studied this question.

synapsesocial.com/papers/689a02afe6551bb0af8cc107 https://doi.org/10.1158/2767-9764.29557184

View Full Paper

Ask AI

Bookmark

Implication

Phase 1b/2 trial examines the effects of decitabine and TP-0903 on treatment response and survival in AML patients, indicating potential benefits for elderly populations.

Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

No abstract yet

Discussion

Member takes

Implication

Key Points

Cite This Study

Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

No abstract yet

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider